Arcutis Q3 2025 net product revenue $99.2M (+122% YoY); turns profitable; FY2026 guidance $455-470M

Arcutis Biotherapeutics, Inc.

2025-Q3 EPS reported -$0.26 revenue$246,569,000

Net product revenue $99.2M (+122% YoY, +22% sequential); driven by ZORYVE cream and foam.
Net income $7.4M ($0.06 EPS) vs net loss $41.5M ($0.33 loss per share) in Q3 2024.
FDA approved ZORYVE cream 0.05% for atopic dermatitis in children 2-5; launch by end of October.
Initial FY2026 net product revenue guidance of $455-$470M; peak ZORYVE sales target $2.6-3.5B.
Phase 2 trials started for ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.